Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe


AMAG Pharma Receives $647 Million Takeover Bid from Luxembourg Firm

Share on Stocktwits


Shares of AMAG Pharmaceuticals traded 44% higher after the company reported it has agreed to be acquired by Covis Group S.à r.l. for $13.75 per share in cash, or approximately $498 million on a fully diluted basis.

Commercial-stage biopharmaceutical firm AMAG Pharmaceuticals Inc. (AMAG:NASDAQ) and Covis Group S.à r.l. of Luxembourg, today announced that "the two companies have entered into a definitive agreement under which Covis will acquire AMAG for $13.75 per share in cash, or approximately $498 million on a fully diluted basis and approximately $647 million on an enterprise basis." The firms noted that the offering price represents about a 46% premium to AMAG's common stock closing price on September 30, 2020.

Covis' CEO Michael Porter remarked, "AMAG's category leading treatments are strong strategic complements to our existing therapeutic portfolio. Through this combination, we believe we will be able to unlock value for all of our stakeholders, employees and patients through the effective and efficient management of these products, coupled with our two companies' longstanding commitment to expanding patient access to therapy and putting patient interests first...We look forward to engaging with the talented team at AMAG as we work together to plan the integration of our two organizations."

AMAG Pharmaceuticals CEO Scott Myers commented, "In the beginning of 2020, AMAG announced that the company had undertaken a strategic review of our product portfolio and strategy, the guiding principles of which included driving near- and long-term profitability and enhancing shareholder value. This strategic review resulted in the company pursuing and accomplishing the divestiture of its women's health assets, and other efforts to streamline and strengthen the core business to position AMAG for the future. Following this initial transformation, our Board of Directors and management team, together with independent legal and financial advisors, thoroughly evaluated the transaction with Covis as well as other strategic options and concluded that it represents the most compelling opportunity for shareholders, providing them certain and immediate cash value. We believe Covis is the right partner for AMAG, especially in light of Covis' shared commitment to ensuring that our therapies will reach patients in need. We are confident the work we've done will continue to thrive under Covis' leadership."

The companies advised that the tender offer is subject to majority shareholder (shares) approval along with customary closing conditions and regulatory approvals. The firms stated that when the tender offer conditions are met and the offer is completed, a 100%-owned subsidiary of Covis will merge with AMAG and any outstanding AMAG shares not tendered in the tender offer will be converted into the right to receive the same $13.75 per share in cash paid in the tender offer.

The report noted that Covis intends to finance the acquisition with cash on hand and some committed debt and equity financing. The companies indicated that the tender offer is expected to commence in October 2020 and to close in November 2020 assuming the transaction is approved under Hart-Scott-Rodino regulations.

The news release stated that the Boards of Directors of each company have already unanimously approved the transaction and that all of AMAG's board members and executive officers have agreed to tender their shares in favor of the transaction.

Covis is a global specialty pharmaceutical company headquartered in Luxembourg and operates facilities in Zug, Switzerland. The firm is engaged in marketing therapeutics for patients with chronic illnesses and life-threatening medical conditions.

AMAG is a commercial-stage biopharmaceutical company based in Waltham, Mass., that is focused on bringing innovative products to patients with unmet medical needs. The firm's pharmaceutical products cover a wide range of treatment areas with a focus on maternal health, anemia management and cancer supportive care.

AMAG Pharmaceuticals began the day with a market capitalization of around $324.1 million with approximately 34.48 million shares outstanding and a short interest of about 29.50%. AMAG shares opened 37% higher today at $12.98 (+$3.50, +36.92%) over yesterday's $9.48 closing price and reached a new 52-week high price this morning of $13.80. The stock has traded today between $12.55 and $13.80 per share and is currently trading at $13.60 (+$4.20, +44.63%).


1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Want to read more about Biotechnology / Pharmaceuticals investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe